Denosumab 60 mg vs 120 mg: What the Prolia and Xgeva Labels and Trials Report
Denosumab 60 mg vs 120 mg is a comparison hospital pharmacies run into often, because the same medicine is stocked in two very different forms under two different brand names. The 60 mg product (sold as Prolia) and the 120 mg product (sold as Xgeva) contain the same antibody, yet their approved uses, labelled schedules […]
Copellor (Ixekizumab) India — What Hospitals and Dermatologists Need to Know
1. What Is Copellor (Ixekizumab)? Copellor® is the brand name for Ixekizumab, a humanised anti-interleukin-17A (anti-IL-17A) IgG4 monoclonal antibody manufactured by Eli Lilly and Company India Pvt Ltd and approved by the Drugs Controller General of India (DCGI). It is available as an 80mg/mL subcutaneous injection in a pre-filled syringe or auto-injector. Ixekizumab works by […]
Endoprost (Alprostadil) India — What Hospitals Need to Know
For hospital pharmacists, neonatologists, vascular surgeons, and urologists sourcing critical-care injectables in India, Endoprost (Alprostadil) is one of the most clinically important — and procurement-sensitive — medicines on any formulary. This guide covers what hospital procurement teams across India need to know about Alprostadil: what it is, which clinical departments depend on it, how it […]
Imfinzi (Durvalumab) in India 2026 — What Hospitals and Oncology Centres Need to Know
Imfinzi is one of the most searched oncology medicines on akpharma.in — generating over 1,400 impressions per month at position 6 on Google, with a click-through rate that suggests the page is being found but not telling visitors enough to bring them through. This article fills that gap. Whether you are a hospital pharmacist managing […]
Checkpoint Inhibitors in India 2026 — What Has Changed and What Hospitals Need to Prepare For
Five years ago, checkpoint inhibitor immunotherapy was a treatment category that most Indian oncology centres had limited access to — expensive, largely imported, and available through relatively few distribution channels. In 2026, the landscape looks fundamentally different. Multiple checkpoint inhibitors are now available in India across different mechanisms, different indications, and increasingly different price points. […]
The Difference Between a Biosimilar and a Generic — What Hospital Pharmacists Need to Know
In hospital pharmacy conversations across India, two words get used interchangeably more often than they should: generic and biosimilar. Both refer to non-originator versions of existing medicines. Both are generally less expensive than the originator product. And both require regulatory approval before they can be sold. But beyond those surface similarities, the two are fundamentally […]
Zoladex 3.6mg vs 10.8mg — Which Formulation Is Right for Your Patient?
It is one of the most common procurement questions that hospital pharmacists and oncology nurses encounter when a patient is first prescribed Zoladex: which one do we order — the 3.6mg or the 10.8mg? The question sounds simple. The answer requires understanding not just the difference in dose and interval but also which indications each […]
Ozempic for Weight Loss in Delhi — What You Need to Know Before Asking Your Doctor
Ozempic has become one of the most searched medicine names in India over the past two years. That search volume is not coming from people with diabetes — although Ozempic is a diabetes medicine and that is what it is approved for. It is coming from people who have read about dramatic weight loss results […]
Does Hormone Therapy Cure Prostate Cancer? What Zoladex Actually Does — and Does Not Do
When a urologist or oncologist recommends Zoladex for prostate cancer, the word that tends to echo in the patient’s mind — and in the minds of their family — is the word they did not hear. The doctor explained what Zoladex does. They explained how it works, what to expect, what the side effects might […]
Why Some Medicines Are Imported Instead of Manufactured in India
Walk into any oncology department at a major Indian hospital and you will find medicines from Germany, the United States, Switzerland, Japan, and the United Kingdom sitting alongside domestically manufactured generics. For most patients and their families, this raises a perfectly reasonable question: why is this medicine coming from abroad? Why isn’t it made here? […]
